Sign In
Buy PTN
$11.77
+0.0500 (+0.427%)
At Close: Jun 22, 2026
Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.
08:00am, Wednesday, 03'rd Jan 2024
BRIDGEWATER, N.J.--(BUSINESS WIRE)-- #HSDD--Cosette Pharmaceuticals Acquires Vyleesi® (Bremelanotide Injection) from Palatin Technologies Inc.
Analysts Say 3 Stocks Have a Combined Upside of 3000%
05:00pm, Saturday, 23'rd Dec 2023
Wall Street analysts can get a bit optimistic with their price targets. So when I see calls for triple-digit upside, I take them with a grain of salt.
Palatin Technologies Sells Vyleesi in $171M Transaction
11:32am, Thursday, 21'st Dec 2023
New York, December 21, 2023 – Palatin Technologies, Inc. (NYSE American: PTN) has completed the sale of Vyleesi® to Cosette Pharmaceuticals, a US-based, specialty pharmaceutical company, for up
Palatin to Report First Quarter Fiscal Year 2024 Results; Teleconference and Webcast to be held on November 14, 2023
07:30am, Thursday, 09'th Nov 2023
CRANBURY, N.J. , Nov. 9, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its first quarter fiscal year 2024 operating results on Tuesday, November 14, 2023, before t
Palatin Technologies, Inc. (PTN) Q4 2023 Earnings Call Transcript
08:31pm, Friday, 29'th Sep 2023
Palatin Technologies, Inc. (NYSE:PTN ) Q4 2023 Earnings Conference Call September 28, 2023 11:00 AM ET Company Participants Carl Spana - President and Chief Executive Officer Steve Wills - Executive V
Palatin to Report Fourth Quarter and Fiscal Year End 2023 Results; Teleconference and Webcast to be held on September 28, 2023
04:00pm, Friday, 22'nd Sep 2023
CRANBURY, N.J. , Sept. 22, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its fourth quarter and fiscal year end 2023 operating results on Thursday, September 28, 2
Palatin Technologies, Inc. (PTN) Reports Q3 Loss, Tops Revenue Estimates
09:53am, Tuesday, 16'th May 2023
Palatin Technologies, Inc. (PTN) came out with a quarterly loss of $0.63 per share versus the Zacks Consensus Estimate of a loss of $0.59. This compares to loss of $0.75 per share a year ago.
Palatin to Report Third Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on May 16, 2023
04:15pm, Thursday, 11'th May 2023
CRANBURY, N.J. , May 11, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its third quarter fiscal year 2023 operating results on Tuesday, May 16, 2023, before the o
Palatin Technologies, Inc. (PTN) Q1 2023 Earnings Call Transcript
02:18pm, Wednesday, 15'th Feb 2023
Palatin Technologies, Inc. (NYSE:PTN ) Q1 2023 Earnings Conference Call February 15, 2023 11:00 AM ET Company Participants Carl Spana - President and CEO Steve Wills - EVP, CFO and COO Conference Call
Palatin to Report Second Quarter Fiscal Year 2023 Results; Teleconference and Webcast to be held on February 15, 2023
07:30am, Friday, 10'th Feb 2023
CRANBURY, N.J. , Feb. 10, 2023 /PRNewswire/ -- Palatin Technologies, Inc. (NYSE American: PTN) will announce its second quarter fiscal year 2023 operating results on Wednesday, February 15, 2023, befo
Palatin Technologies, Inc. (PTN) Reports Q1 Loss, Tops Revenue Estimates
01:55pm, Monday, 14'th Nov 2022 Zacks Investment Research
Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of 35.82% and 8.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the
Palatin Technologies, Inc. (PTN) Q1 2023 Earnings Call Transcript
12:47pm, Monday, 14'th Nov 2022
Palatin Technologies, Inc. (NYSE:PTN ) Q1 2023 Earnings Conference Call November 14, 2022 11:00 AM ET Company Participants Carl Spana - President and Chief Executive Officer Steve Wills - Executive Vi
Palatin Technologies, Inc. (PTN) Reports Q1 Loss, Tops Revenue Estimates
10:32am, Monday, 14'th Nov 2022
Palatin Technologies, Inc. (PTN) delivered earnings and revenue surprises of 35.82% and 8.75%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the
Solid Biosciences Inc. (SLDB) Reports Q3 Loss, Lags Revenue Estimates
01:55pm, Thursday, 10'th Nov 2022 Zacks Investment Research
Solid Biosciences Inc. (SLDB) delivered earnings and revenue surprises of -4.63% and 100%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stoc
Armata Pharmaceuticals, Inc. (ARMP) Reports Q3 Loss, Misses Revenue Estimates
11:45pm, Wednesday, 09'th Nov 2022 Zacks Investment Research
Armata Pharmaceuticals, Inc. (ARMP) delivered earnings and revenue surprises of 11.11% and 3.04%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for t
